Ann Goebel-Fabbri, PhD, a clinical psychologist in Boston, Massachusettes, discusses how limited research on patients with type 1 diabetes (T1D) and eating disorders hinders progress on developing effective interventions.
Research looking at specific treatments for eating disorders and type 1 diabetes is in very early stages, said Ann Goebel-Fabbri, PhD, a clinical psychologist practicing in Boston, Massachusettes.
Transcript
What challenges do patients with type 1 diabetes and eating disorders face?
What's been studied the most at this point, in terms of eating disorders and diabetes, is a very specific symptom that only people with type 1 diabetes can actually have. Namely, people who intentionally take less insulin than their body actually needs for the purposes of running their glucose levels high and intentionally purging calories in that way. You can imagine this is a very dangerous behavior that actually comes with a tremendous amount of medical complications happening at an earlier age and also at a shorter duration of diabetes than we would expect. In a sense, if you think about it, people who are experiencing this symptom are turning the clock back to before we had these high-tech, health and life-sparing technologies and treatments for type 1 diabetes.
What are some effective and practical approaches for treating these concurrent conditions, and what are some limitations to these approaches?
The limitations are that we really don't know. That's the problem. The research is just out of the very, very early stages in terms of looking at specific treatments for eating disorders and type 1 diabetes. There's some early pilot data that shows that women with type 1 diabetes seem to drop out of treatment more often than women without diabetes and that they have worse treatment outcomes as well. The question that that raises for me is, is that because these women are in some sort of standard eating disorder treatment that hasn't perhaps been tailored to the specific needs of patients with T1D? That level of intervention is what's just starting to be looked at in terms of how to best design such a thing and how to then go about evaluating it.
The Challenge of Addressing Drug Spend to Drive Down Total Cost of Care in EOM
October 27th 2024Stuart Staggs, vice president of transformation and shared services at McKesson, explained that oncology practices in the Enhancing Oncology Model (EOM) have a tough job driving down costs when drug costs make up a larger portion of the total cost of care.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Targeting Progression: Amivantamab’s Role in NSCLC After Osimertinib
October 24th 2024Amivantamab's role in non–small cell lung cancer (NSCLC) has been a highlight of the lung cancer space this year, with the 2 most recent approvals based on data from the MARIPOSA and MARIPOSA-2 trials.
Read More
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More